Advanced search×

Performance evaluation of the ADVIA 2120 hematology analyzer: an international multicenter clinical trial.

Neil N Harris, Josep Maria JM Jou, Gianluigi G Devoto, J J Lotz, James J Pappas, David D Wranovics, Mary M Wilkinson, Suzanne R SR Fletcher, and Alexander A Kratz

Lab Hematol 11(1):62-70 (2005) PMID 15790554

Automated cell counters are widely used in modern clinical laboratories to provide reliable, fast, and cost-effective complete blood counts (CBCs), white blood cell differentials, and reticulocyte measurements. In addition, some advanced instruments provide novel parameters, such as the hemoglobin content of reticulocytes or the percentage of hypochromic cells, and are capable of analysis of a variety of body fluids. Bayer recently introduced the ADVIA 2120 system as an automation-ready cell counter for mid- to high-volume testing in the clinical laboratory. This instrument, which builds on the established technology of the ADVIA 120 system, operates with a cyanide-free method for hemoglobin measurement, has a new user interface, and can routinely analyze biological fluid samples in addition to blood. We used 749 samples from 6 worldwide trial sites to evaluate the clinical performance of this new device. Accuracy of the ADVIA 2120 system versus its predecessor model, the ADVIA 120 system, was excellent for all CBC and white cell differential parameters and reticulocyte counts (all correlation coefficients except for basophils >0.9). Correlation of the white cell differential with the standard manual method and within-run precision of the ADVIA 2120 system also was very good. Use of the novel cyanide-free method for hemoglobin measurement had no clinically significant impact on hemoglobin results, even in patients with hemoglobinopathies. We concluded that the ADVIA 2120 system has clinically equivalent performance to the ADVIA 120 system.

Referenced by 1 articles

DOI: 10.1532/LH96.04064
Version: za2963e q8za8 q8zb1 q8zc9 q8zdd q8ze9 q8zf9 q8zgc

Similar articles you may find interesting…

  1. The ADVIA 2120 hematology system: flow cytometry-based analysis of blood and body fluids in the routine hematology laboratory.
    Neil N Harris, Jolanta J Kunicka, and Alexander A Kratz

    Lab Hematol 11(1):47-61 (2005) PMID 15790553

    We explain the underlying technology of the ADVIA 2120, provide linearity ranges, method-specific reference ranges, and stability data, and describe novel parameters and applications that are unique to the methodology used by this instrument. Finally, we discuss research applications and future dire...
  2. Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays.
    Shella K SK Mongia, Randie R RR Little, ... William L WL Roberts

    Am J Clin Pathol 130(1):136-40 (2008) PMID 18550483

    We evaluated the effects of HbC and HbS traits on the results of 14 commercial HbA1c methods that use boronate affinity, enzymatic, immunoassay, and ion exchange methods. Whole blood samples from people homozygous for HbA or heterozygous for HbC or HbS were analyzed for HbA1c. Results for each sampl...
  3. Implementing neonatal screening for haemoglobinopathies in the Netherlands.
    Marelle J MJ Bouva, Karin K Mohrmann, ... Piero C PC Giordano

    J Med Screen 17(2):58-65 (2010) PMID 20660432

    The pilot screening resulted in 188 abnormal patterns. The three HPLC devices presented comparable within- and between-run precision and detected the abnormal samples similarly. The high throughput, sampling systems, presentation of results, and integration of the chromatograms, however, were differ...